Use of icariin and epimedium flavonoids containing icariin to treat diseases associated with myelin sheath lesion
First Claim
1. A method for alleviating or repairing a disease and/or disorder associated with a nervous system myelin sheath lesion, comprising administering icariin to a patient in need thereof:
- further comprising any one of the following items a) to b);
a) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
optical neuromyelitis, acute disseminated encephalomyelitis, diffuse sclerosis, concentric circle sclerosis, central pontine myelinolysis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy;
orb) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
subacute combined degeneration caused by nutrition deficiency diseases, subacute sclerosing panencephalitis caused by viral infection or progressive multifocal leukoencephalopathy, and diabetic neuropathy;
wherein icariin is administered in amounts from 0.1 μ
g to 250 mg per kilogram bodyweight per day.
1 Assignment
0 Petitions
Accused Products
Abstract
New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention. Specifically, uses of compounds of Formula I or Epimedium containing compounds of formula I, Epimedium flavanoids, or extracts of Epimedium in manufacturing medicaments for treating, preventing, reducing and/or relieving diseases and/or conditoins related to neural myelin sheath impairments, or use of above materials in manufacturing medicaments for relieving demyelination and/or promoting repair of myelin sheath are provided by the present application, wherein, R1 is selected from H, halogen, —C1-6 alkyl, and —C(O)—C1-4 alkyl
2 Citations
11 Claims
-
1. A method for alleviating or repairing a disease and/or disorder associated with a nervous system myelin sheath lesion, comprising administering icariin to a patient in need thereof:
-
further comprising any one of the following items a) to b); a) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
optical neuromyelitis, acute disseminated encephalomyelitis, diffuse sclerosis, concentric circle sclerosis, central pontine myelinolysis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy;
orb) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
subacute combined degeneration caused by nutrition deficiency diseases, subacute sclerosing panencephalitis caused by viral infection or progressive multifocal leukoencephalopathy, and diabetic neuropathy;wherein icariin is administered in amounts from 0.1 μ
g to 250 mg per kilogram bodyweight per day. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A method for alleviating or repairing a disease and/or disorder associated with a nervous system myelin sheath lesion, comprising administering icariin to a patient in need thereof:
-
further comprising any one of the following items a) to b); a) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
optical neuromyelitis, acute disseminated encephalomyelitis, diffuse sclerosis, concentric circle sclerosis, central pontine myelinolysis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy;
orb) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
subacute combined degeneration caused by nutrition deficiency diseases, subacute sclerosing panencephalitis caused by viral infection or progressive multifocal leukoencephalopathy, and diabetic neuropathy,wherein the icariin is administered in a pharmaceutical composition comprising from 0.01 μ
g to 2000 mg icariin per 100 g pharmaceutical composition and a pharmaceutically acceptable carrier.
-
-
11. A method for alleviating or repairing a disease and/or disorder associated with a nervous system myelin sheath lesion, comprising administering an epimedium flavonoid comprising from 50 to 90 wt. % icariin to a patient in need thereof:
-
further comprising any one of the following items a) to b); a) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
optical neuromyelitis, acute disseminated encephalomyelitis, diffuse sclerosis, concentric circle sclerosis, central pontine myelinolysis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy;
orb) the disease and/or disorder associated with nervous system myelin sheath lesion is selected from;
subacute combined degeneration caused by nutrition deficiency diseases, subacute sclerosing panencephalitis caused by viral infection or progressive multifocal leukoencephalopathy, and diabetic neuropathy;wherein icariin is administered in amounts from 0.1 μ
g to 250 mg per kilogram bodyweight per day.
-
Specification